Plain-English translation of NCT06616142 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This pilot study is testing a new PET imaging scan called para-chloro-2-[18F]fluoroethyl-etomidate ([18F]CETO) to help doctors better diagnose and classify primary aldosteronism—a form of high blood pressure caused by the adrenal glands. The scan uses a special tracer that highlights aldosterone-producing tissue in the adrenal glands. Researchers hope this medication will provide a faster, less invasive alternative to current diagnostic procedures.
Currently, doctors use an invasive procedure called adrenal vein sampling to figure out which type of primary aldosteronism a patient has—but this procedure is time-consuming, requires special expertise, carries risks, and is expensive. This trial exists because there is a real need for a simpler, safer, and more accessible way to make this important diagnosis.
You likely qualify if…
You likely don't qualify if…
If you join this study, you will receive two imaging scans at the research center: a PET scan using the new tracer medication and a water scan to measure blood flow to your adrenal glands. You will also need to take a dose of dexamethasone before the scan and temporarily stop certain blood pressure medications. The study involves 12 patients total, and researchers will compare your scan results to your previous diagnostic testing to see how well the new scan works.
AI-generated summary from trial data · Aug 28, 2026 · Not medical advice
Netherlands